The estimated Net Worth of Gary Patou is at least $1.09 millió dollars as of 13 December 2023. Gary Patou owns over 18,978 units of Xenon Pharmaceuticals Inc stock worth over $189,462 and over the last 12 years he sold XENE stock worth over $896,923. In addition, he makes $0 as Independent Director at Xenon Pharmaceuticals Inc.
Gary has made over 19 trades of the Xenon Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 18,978 units of XENE stock worth $758,930 on 13 December 2023.
The largest trade he's ever made was exercising 40,000 units of Xenon Pharmaceuticals Inc stock on 1 July 2013 worth over $64,400. On average, Gary trades about 7,179 units every 112 days since 2012. As of 13 December 2023 he still owns at least 4,902 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Gary Patou stock trades at the bottom of the page.
Dr. Gary Patou M.D. serves as Independent Director of the Company. Dr. Patou has been an Executive Partner at MPM Capital, a venture capital fund focused on life sciences companies, since 2005, and has served as interim Chief Medical Officer in various MPM portfolio companies. Since 2014, Dr. Patou has served as a senior medical advisor to Chiasma, Inc. Previously, Dr. Patou served as Chief Medical Officer for Pacira Pharmaceuticals, Inc. from 2009 to 2015, and True North Therapeutics, Inc. from January 2017 to June 2017. Prior to joining Pacira, Dr. Patou was Chief Medical Officer at Peplin Inc. from July 2006 to April 2007, and Chief Medical Officer of Cerimon Pharmaceuticals, Inc. from June 2005 to June 2006. Prior to joining MPM, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corp. from February 2004 to April 2005 following its merger with GeneSoft Pharmaceuticals, Inc. Prior to GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine and received his B.Sc. from University of London and his M.D. from University College London. Our Board believes that Dr. Patou is qualified to serve on our Board because of his scientific background and his senior management experience in the pharmaceutical industry.
Gary Patou is 61, he's been the Independent Director of Xenon Pharmaceuticals Inc since 2004. There are 5 older and 16 younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.
Gary's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog... és Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: